New York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The ...
Nina Bauer of FUJIFILM Cellular Dynamics shares insight on addressing challenges and supporting developers heading towards commercialization.
XCells Biotechnologies USA, Inc. ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem ...
GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients ...
Morning Overview on MSN
Japan approves world-first iPSC therapy for Parkinson’s disease
Japan’s health ministry has endorsed the first stem-cell therapy derived from induced pluripotent stem cells (iPSCs) for ...
In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...
Flow cytometers, droplet dispensers, and limiting dilution techniques aimed at depositing a single iPSC in a well, often create a strenuous and unnatural environment that leads to low clonal survival ...
(MENAFN- GlobeNewsWire - Nasdaq) The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results